Mandate

Vinge advises Industrifonden in connection with its investment in Agteria Biotech

Vinge has advised Industrifonden in connection with their participation as lead investor, together with AgriZeroNZ, in the seed financing round in Agteria Biotech AB.

Agteria Biotech AB is a Swedish start-up dedicated to reducing 1% of the global greenhouse gas emissions through its patent-pending molecule that significantly reduces methane emissions from cattle. The new funding will enable the company to advance towards regulatory approval for its methane-reducing molecule, focusing on safety studies for animals, consumers, and the environment.

The Vinge team consisted primarily of JJohan Larsson, Maria Dahlin Kolvik, Ian Linde (M&A), Åsa Hellstadius, Rebecka Målquist (IP), Simon Söderholm and Agnes Pigg (Employment).

Related

Vinge advises Altor on its public offer for Sleep Cycle

Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026

Vinge advises SEB Kort in connection with a cross-border merger with AirPlus

Vinge advised SEB Kort in connection with a cross-border merger whereby the subsidiary AirPlus has been absorbed into SEB Kort.
August 06, 2026

Vinge advises Altor- and Stena-owned Gunnebo in connection with the divestment of Gunnebo Entrance Control AB to ASSA Abloy

Vinge has advised Gunnebo in connection with its divestment of Gunnebo Entrance Control AB to ASSA Abloy.
August 04, 2026